Oncotarget

Research Papers:

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers

Federica Turdo, Francesca Bianchi, Patrizia Gasparini, Marco Sandri, Marianna Sasso, Loris De Cecco, Luca Forte, Patrizia Casalini, Piera Aiello, Lucia Sfondrini, Roberto Agresti, Maria Luisa Carcangiu, Ilaria Plantamura, Gabriella Sozzi, Elda Tagliabue and Manuela Campiglio _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69649-69665. https://doi.org/10.18632/oncotarget.11935

Metrics: PDF 1261 views  |   HTML 1025 views  |   ?  


Abstract

Federica Turdo1,*, Francesca Bianchi1,7,*, Patrizia Gasparini2, Marco Sandri1, Marianna Sasso1, Loris De Cecco3, Luca Forte1, Patrizia Casalini1, Piera Aiello1, Lucia Sfondrini7, Roberto Agresti4, Maria Luisa Carcangiu5, Ilaria Plantamura6, Gabriella Sozzi2, Elda Tagliabue1,#, Manuela Campiglio1,#

1Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

2Tumor Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

3Functional Genomic Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

4Division of Surgical Oncology, Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

5Division of Breast Anatomy Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

6Start-Up Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

7Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy

*These authors contributed equally to this work

#These authors contributed equally and share senior authorship

Correspondence to:

Manuela Campiglio, email: manuela.campiglio@istitutotumori.mi.it, manuela.campiglio@me.com

Keywords: triple-negative breast cancer, CDCP1, CDCP1 copy number, prognosis, metastasis

Received: September 10, 2015     Accepted: August 27, 2016     Published: September 10, 2016

ABSTRACT

CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities—ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11935